On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.

The Coalition for Epidemic Preparedness Innovations (CEPI) supported the development of Clover’s COVID-19 vaccine candidate and funded the development, including the Phase 2/3 trial, through licensure.